Related Experiment Video
Updated: Jan 26, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia
Caroline Beaulieu1, Lisa Kurczewski2, Vishal Yajnik3
1Department of Pharmacy, Virginia Commonwealth University Health, 401 North 12th Street, P.O. Box 980042, Richmond, VA, 23298-0042, USA. dr.carolinebeaulieu@gmail.com.
Abstract:
Drug-induced thrombocytopenia (DITP) has been described as a sudden and severe hematologic complication of piperacillin/tazobactam. The proposed mechanism by which piperacillin/tazobactam causes DITP involves the formation of a covalent bond to platelet membrane protein thereby inducing a humoral immune response. Given the immunogenic nature of this adverse event and the structural similarities across beta-lactam antibiotics, the potential for cross-reactivity between agents within the class should be considered. However, the structural moiety of piperacillin/tazobactam responsible for this immunogenic response has not been identified-the relationship between structure and activity for this phenomenon remains unknown. Data on the safety and cross-reactivity of other beta-lactam agents in this setting is lacking. We report the first case of piperacillin/tazobactam DITP successfully challenged by the use of cefepime for the treatment of aspiration pneumonia. Further studies are needed to determine the structural moiety of piperacillin/tazobactam responsible for this immunogenic response and evaluate the safety of other beta-lactam antibiotics in this clinical setting.
Insights
Piperacillin/tazobactam can cause drug-induced thrombocytopenia (DITP) through an immune response. Cefepime was safely used in a patient with piperacillin/tazobactam DITP, suggesting potential for cross-reactivity studies.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Piperacillin/tazobactam is associated with drug-induced thrombocytopenia (DITP), a severe hematologic complication.
- The mechanism involves a humoral immune response triggered by piperacillin/tazobactam binding to platelet proteins.
- Cross-reactivity among beta-lactam antibiotics is a concern due to structural similarities, but the specific immunogenic moiety is unknown.
Purpose of the Study:
- To investigate the potential for cross-reactivity in piperacillin/tazobactam-induced thrombocytopenia.
- To evaluate the safety of alternative beta-lactam antibiotics in patients with piperacillin/tazobactam DITP.
- To highlight the need for further research into the structure-activity relationship of DITP caused by beta-lactams.
Main Methods:
- Case report of a patient with piperacillin/tazobactam DITP.
- Successful treatment challenge with cefepime for aspiration pneumonia.
- Review of existing literature on beta-lactam induced thrombocytopenia and cross-reactivity.
Main Results:
- The first reported case of piperacillin/tazobactam DITP successfully managed with cefepime.
- Cefepime administration did not exacerbate thrombocytopenia in this patient.
- This suggests potential tolerance or lack of cross-reactivity between piperacillin/tazobactam and cefepime in DITP.
Conclusions:
- Cefepime may be a safe alternative in patients with piperacillin/tazobactam-induced thrombocytopenia.
- Further studies are required to elucidate the specific structural components of piperacillin/tazobactam responsible for DITP.
- Evaluating the safety and cross-reactivity of other beta-lactam antibiotics is crucial for clinical practice.
Related Concept Videos
Induced-fit Model
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic...
Spontaneous and Induced Mutations
Induced Electric Dipoles
Since the absolute value of potential energy holds no physical meaning, its zero value can be chosen as per...
Induced Electric Fields

